Glenmark Pharmaceuticals Limited (BSE: 532296 / NSE: GLENMARK)
Technical Analysis & Key Levels
-
Reference Closing Price: ₹ 2,440
-
Immediate Support Level: ₹2,424
-
Strong Support Level: ₹2,408 (Key swing base & 20-day EMA zone)
-
Short-term Levels: ₹2,474 – ₹2,490
-
Bullish Breakout Point: Above ₹2,503
Company Overview
-
Business Profile: Leading global research-led pharmaceutical company focused on branded generics, specialty formulations, active pharmaceutical ingredients (APIs), and novel biologics across respiratory, dermatology, and oncology domains.
-
Face Value: ₹1
-
Promoter Holding: ~46.7% (backed by strong domestic and foreign institutional holding)
Financials & Outlook
-
Quarterly Performance: Robust operational revenue growth supported by steady domestic brand sales and international formulations, delivering expanding EBITDA margins and recovering net profits.
-
Growth Drivers: Expansion of specialty drug portfolio, new product launches in dermatological and respiratory segments, and strong operational leverage.
-
Long-term View: Structurally positive outlook driven by earnings recovery, active deleveraging, and strong global market positioning.
- All content and securities mentioned are strictly for illustration and are not buy, sell, or hold recommendations. Investments in the securities market are subject to market risks, Carefully read and agree to all disclaimers and related documents on www.nikhilbhatt.in before investing.
